Oropharyngeal candidosis (OPC) is an opportunistic fungal infection that is commonly found in HIV-infected patients, even in the twenty-first century. is the main pathogen, but other species have been isolated. OPC usually presents months or years before other severe opportunistic infections and may indicate the presence or progression of HIV disease. The concept of OPC as a biofilm infection has changed our understanding of its pathobiology. Various anti-fungal agents (both topical and systemic) are available to treat OPC. However, anti-fungal resistance as a result of the long-term use of anti-fungal agents and recurrent oropharyngeal infection in AIDS patients require alternative anti-fungal therapies. In addition, both identifying the causative species and conducting anti-fungal vulnerability testing can improve a clinician's ability to prescribe effective anti-fungal agents. The present review focuses on the current findings and therapeutic challenges for HIV-infected patients with OPC.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5962761 | PMC |
http://dx.doi.org/10.3389/fmicb.2018.00980 | DOI Listing |
Transl Vis Sci Technol
January 2025
Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Purpose: To clarify the clinical and imaging characteristics of Candida keratitis using in vivo confocal microscopy (IVCM) for improved early diagnosis and management.
Methods: A retrospective study of 40 patients with Candida keratitis at Beijing Tongren Hospital from January 2015 to December 2023 was conducted. Data included demographics, risk factors, clinical assessments, lab tests, and IVCM images.
Infect Dis Rep
January 2025
Mediprobe Research Inc., London, ON N5X 2P1, Canada.
Background/objectives: In an 18- to 24-month Treatment Phase with once-daily efinaconazole 10% solution, subjects with onychomycosis showed an increased rate of cure at Month 24 versus the phase III trials. In order to further improve efficacy, we initiated an extended intermittent efinaconazole Maintenance Phase with use 2-3 times weekly for an additional 24 months from Month 24 to Month 48. These are the first data presented for a 48-month efinaconazole use period.
View Article and Find Full Text PDFJAAPA
February 2025
At the time this article was written, Anna Morgan was a student in the PA program at the University of North Texas Health Science Center (UNT HSC) in Fort Worth, Tex. She now practices in urgent care at Dignity Health-Mercy Medical Group in Sacramento, Calif. Stephen James Hoyt is a hospitalist at the John Peter Smith Hospital in Fort Worth. Jamie Park practices in emergency medicine and is an assistant professor in the PA program at UNT HSC. Vic Holmes is an associate professor in the PA program at UNT HSC, specializes in the field of family medicine, and is chair of the North Texas Regional Institutional Review Board. The authors have disclosed no potential conflicts of interest, financial or otherwise.
The incidence of coccidioidomycosis has been rising in the past decade. This case report focuses on a man with a history of persistent migraine who presented to the ED with altered mental status. After cerebrospinal fluid testing, the patient was diagnosed with coccidioidal meningitis and treated with lifelong antifungal therapy.
View Article and Find Full Text PDFMycoses
January 2025
Departamento Micología-Instituto Nacional de Enfermedades Infecciosas "Dr. Carlos G. Malbrán", Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina.
Background: Epidemiological surveillance of Candidozyma sp. has become important because many species of this new genus have been reported to be responsible for nosocomial outbreaks and to exhibit elevated minimal inhibitory concentrations (MIC) to one or more classes of antifungal drugs.
Objectives: To describe the genetic relationships among Argentinian clinical isolates belonging to the Candidozyma genus and to study the molecular mechanisms associated with antifungal resistance.
Mycobiology
December 2024
Department of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia.
Fungi and their natural products, like secondary metabolites, have gained a huge demand in the last decade due to their increasing applications in healthcare, environmental cleanup, and biotechnology-based industries. The fungi produce these secondary metabolites (SMs) during the different phases of their growth, which are categorized into terpenoids, alkaloids, polyketides, and non-ribosomal peptides. These SMs exhibit significant biological activity, which contributes to the formulation of novel pharmaceuticals, biopesticides, and environmental bioremediation agents.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!